Valuation: Agenus Inc.

Market Cap 207M 181M 168M 154M 291M 19.96B 296M 2B 786M 9.77B 777M 760M 33.64B P/E 2026 *
7.47x
P/E 2027 * -31.1x
Enterprise Value 207M 181M 168M 154M 291M 19.96B 296M 2B 786M 9.77B 777M 760M 33.64B EV / Sales 2026 *
1.12x
EV / Sales 2027 * 1.57x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day-0.80%
1 week-18.79%
Current month+62.42%
1 month+65.67%
3 months+12.44%
6 months+47.48%
Current year+58.28%
1 week 4.66
Extreme 4.655
5.46
1 month 2.85
Extreme 2.85
8.7
Current year 2.71
Extreme 2.71
8.7
1 year 2.71
Extreme 2.71
8.7
3 years 1.38
Extreme 1.38
32.8
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 30/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/10/2021
Director TitleAgeSince
Chairman 73 03/11/2010
Director/Board Member 68 07/03/2007
Director/Board Member 68 06/12/2006
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Free

Chief Executive Officer

4,852 0.0117%
01/07/26 Free

Director

2,268 0.0054%
01/07/26 Free

Director

8,547 0.0205%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%-18.79%-19.19%-84.85% 207M
-0.94%-4.26%-0.71%+13.59% 48.71B
-3.10%-1.94%+370.99%+572.60% 38.35B
-0.46%+2.18%+5.44%+61.01% 34.53B
-1.14%-1.76%+26.94%-9.93% 34.03B
-1.82%-1.43%+0.52%+31.85% 26.77B
-3.54%-5.08% - - 15.64B
-1.82%-0.43%+69.28%+113.82% 15.08B
-1.83%+1.10%+13.28%+14.17% 14.18B
-2.25%+0.05%+15.77%-32.83% 12.73B
Average -1.78%-2.89%+53.59%+75.49% 24.02B
Weighted average by Cap. -1.71%-1.45%+74.55%+119.00%

Financials

2026 *2027 *
Net sales 185M 162M 150M 138M 260M 17.81B 264M 1.79B 701M 8.71B 694M 678M 30.02B 131M 115M 106M 97.95M 185M 12.68B 188M 1.27B 499M 6.2B 494M 483M 21.37B
Net income 44.8M 39.27M 36.3M 33.38M 62.99M 4.32B 64M 434M 170M 2.11B 168M 165M 7.28B -17.8M -15.6M -14.42M -13.26M -25.03M -1.72B -25.43M -172M -67.6M -840M -66.84M -65.38M -2.89B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
20/07/26 US$4.970 -0.80% 1,969,278
17/07/26 US$5.010 +0.20% 1,754,750
16/07/26 US$5.000 -0.20% 2,696,460
15/07/26 US$5.010 -1.38% 4,491,064
14/07/26 US$5.080 -16.99% 11,110,968
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.970USD
Average target price
30.00USD
Spread / Average Target
+503.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock